Skip to main content
SpringerLink
Log in

Prise en charge préventive et curative des mucites du tractus digestif (mucites buccopharyngées, œsogastro-intestinales et anorectales)

  • Recommandations/Guidelines
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Bensadoun RJ, Bénézery K, Dassonville O, et al. (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCCGORTEC). Int J Radiat Oncol Biol Phys 64: 983–994

    Article  PubMed  CAS  Google Scholar 

  2. Calais G, Alfonsi M, Bardet E, et al. (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91: 2081–2086

    Article  PubMed  CAS  Google Scholar 

  3. Cascinu S, Bichisao E, Amadori D, et al. (2000) High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer 8: 65–67

    PubMed  CAS  Google Scholar 

  4. Citron ML, Berry DA, Cirrincione C, et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8): 1431–1439. Epub 2003 Feb 13

    Article  PubMed  CAS  Google Scholar 

  5. Clark JW (2006) Molecular targeted drugs and growth factor receptor inhibitors. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice, 4th edition. Lippincott, Williams & Wilkins, Philadelphia, pp 641–665

    Google Scholar 

  6. Denis F, Garaud P, Bardet E, et al. (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22: 69–76

    Article  PubMed  Google Scholar 

  7. Elting LS, Keefe DM, Sonis ST, et al. (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 113: 2704–2713

    Article  PubMed  Google Scholar 

  8. French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19(3): 602–611

    Google Scholar 

  9. Freyer G, Delozier T, Lichinister M, et al. (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21(1): 35–40. Epub 2003 Jan 1

    PubMed  CAS  Google Scholar 

  10. Fumoleau P, Largillier R, Clippe C, et al. (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40(4): 536–542

    Article  PubMed  CAS  Google Scholar 

  11. Gebbia V, Carreca I, Testa A, et al. (2001) Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 4:443–445

    Article  Google Scholar 

  12. Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26): 2733–2743

    Article  PubMed  CAS  Google Scholar 

  13. Harris AG, O’Dorisio TM, Woltering EA, et al. (1995) Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 40: 1464–1473

    Article  PubMed  CAS  Google Scholar 

  14. Jones JA, Avritscher EB, Cooksley CD, et al. (2006) Epidemiology of treatment associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14: 505–515

    Article  PubMed  Google Scholar 

  15. Jones SE, Erban J, Overmoyer B, et al. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542–5551

    Article  PubMed  CAS  Google Scholar 

  16. Jones SE, Savin MA, Holmes FA, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381–5387

    Article  PubMed  CAS  Google Scholar 

  17. Keefe DM, Gibson RJ (2007) Mucosal injury from targeted anticancer therapy. Support Care Cancer 15: 483–490

    Article  PubMed  Google Scholar 

  18. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820–831

    Article  PubMed  CAS  Google Scholar 

  19. Lutgens LC, Blijlevens NM, Deutz NE, et al. (2005) Monitoring myeloablative therapyinduced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 103: 191–199

    Article  PubMed  Google Scholar 

  20. Martin M, Pienkowski T, Mackey J, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22): 2302–2313

    Article  PubMed  CAS  Google Scholar 

  21. Martin M, Segui MA, Anton A, et al. (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363: 2200–2210

    Article  PubMed  CAS  Google Scholar 

  22. Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26): 2666–2676

    Article  PubMed  CAS  Google Scholar 

  23. Moebus V, Jackisch C, Lueck HJ, et al. (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17): 2874–2880. Epub 2010 May 10

    Article  PubMed  CAS  Google Scholar 

  24. O’shaughnessy J, Miles D, Vukelja S, et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12): 2812–2823

    Article  PubMed  Google Scholar 

  25. Passardi A, Maltoni R, Milandri C, et al. (2007) Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: Drug sequencing based on clinical modelling studies. Oncology 72: 118–124

    Article  PubMed  CAS  Google Scholar 

  26. Peterson DE, Barker NP, Akhmadullina LI, et al. (2009) Phase II, randomized, doubleblind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 27: 4333–4338

    Article  PubMed  CAS  Google Scholar 

  27. Peterson DE, Bensadoun RJ, Roila F, et al. (2010) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5): v261–v265

    Article  PubMed  Google Scholar 

  28. Peterson DE, Keefe DM, Hutchins RD, et al. (2006) Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice. Support Care Cancer 14: 499–504

    Article  PubMed  Google Scholar 

  29. Raber-Durlacher JE, Abraham-Inpijn L, van Leeuwen EF, et al. (1989) The prevention of oral complications in bone-marrow transplantations by means of oral hygiene and dental intervention. Neth J Med 34: 98–108

    PubMed  CAS  Google Scholar 

  30. Rask C, Albertioni F, Bentzen SM, et al. (1998) Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol 37: 277–284

    Article  PubMed  CAS  Google Scholar 

  31. Roché H, Fumoleau P, Spielmann M, et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24(36): 5664–5671

    Article  PubMed  Google Scholar 

  32. Rosen LS, Abdi E, Davis ID, et al. (2006) Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil based chemotherapy. J Clin Oncol 24: 5194–5200

    Article  PubMed  CAS  Google Scholar 

  33. Rubenstein EB, Peterson DE, Schubert M, et al. (2004) Clinical practice guidelines for the prevention and treatment of cancer therapyinduced oral and gastrointestinal mucositis. Cancer 100(9 Suppl): 2026–2046

    Article  PubMed  Google Scholar 

  34. Ruiz-Arguelles GJ, Coconi-Linares LN, Garce’s-Eisele J, et al. (2007) Methotrexate induced mucositis in acute leukemia patients is not associated with the MTHFR677T allele in Mexico. Hematology 12: 387–391

    Article  PubMed  CAS  Google Scholar 

  35. Sankhala K, Mita A, Kelly K, et al. (2009) The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 4: 135–142

    Article  PubMed  Google Scholar 

  36. Sartori S, Trevisani L, Nielsen I, et al. (2000) Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 18(3): 463–467

    PubMed  CAS  Google Scholar 

  37. Schneider M, Etienne MC, Milano G, et al. (1995) Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 13: 1656–1662

    PubMed  CAS  Google Scholar 

  38. Schwab M, Zanger UM, Marx C, et al. (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26: 2131–2138

    Article  PubMed  CAS  Google Scholar 

  39. Serin D, Verrill M, Jones A, et al. (2005) Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. Br J Cancer 92(11): 1989–1996

    Article  PubMed  CAS  Google Scholar 

  40. Sonis ST, Elting LS, Keefe D, et al. (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(9 Suppl): 1995–2025

    Article  PubMed  Google Scholar 

  41. Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5(9 Suppl 4): 3–11

    PubMed  CAS  Google Scholar 

  42. Sparano JA, Wang M, Martino S, et al. (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16): 1663–1671

    Article  PubMed  CAS  Google Scholar 

  43. Thyss A, Milano G, Renee N, et al. (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16: 64–66

    Article  PubMed  CAS  Google Scholar 

  44. Tooley KL, Howarth GS, Butler RN (2009) Mucositis and non-invasive markers of small intestinal function. Cancer Biol Ther 8: 753–758

    PubMed  CAS  Google Scholar 

  45. Tubiana-Mathieu N, Bougnoux P, Becquart D, et al. (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer 101(2):232–237. Epub 2009 Jul 7

    Article  PubMed  CAS  Google Scholar 

  46. Worthington HV, Clarkson JE, Eden OB (2007) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (4):CD000978

Download references

Authors
  1. R. -J. Bensadoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. -P. Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Di Palma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Scotté
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Mayeur
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Bensadoun, R.J., Durand, J.P., Di Palma, M. et al. Prise en charge préventive et curative des mucites du tractus digestif (mucites buccopharyngées, œsogastro-intestinales et anorectales). Oncologie 13, 825–832 (2011). https://doi.org/10.1007/s10269-011-2095-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-011-2095-8

Search

Navigation